Mymetics Corporation   Report issue

For profit Phase 1
Founded: Epalinges Switzerland (1990)

Organization Overview

First Clinical Trial
2008
NCT00513669
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (3)

mym-v101 (1 trial)

pev301 (1 trial)

virosomal influenza vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 1)

Malaria, Falciparum (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3